drug_type
RELEVANT_DRUG
intervention_type
Experimental
drug_description
HER2-targeted antibody–drug conjugate linking trastuzumab to a topoisomerase I inhibitor (DXd); binds HER2, mediates ADCC, internalizes and releases DXd to induce DNA damage (bystander effect).
nci_thesaurus_definition
NCI thesaurus definition not available.
drug_mesh_term
Trastuzumab Deruxtecan
drug_category
ANTIBODY DRUG CONJUGATE
drug_class
Conjugate
drug_delivery_route
Intravenous
drug_mechanism_of_action
HER2-targeted antibody–drug conjugate: trastuzumab binds HER2, inhibits signaling and mediates ADCC; the complex is internalized and releases the topoisomerase I inhibitor DXd, causing DNA damage and cell death with a bystander effect.
drug_name
Trastuzumab deruxtecan (T-DXd)
nct_id_drug_ref
NCT06253650